Vazobral

General characteristics. Structure:

Active components: дигидроэргокриптин and-mezilat 4,0 mg; caffeine of 40,0 mg

Excipients: lactoses monohydrate, microcrystallic cellulose, magnesium stearate, anhydrous dioxide of silicon colloid.

Pharmacological properties:

The combined drug, a-Digidroergokriptin - dehydrogenated derivative an ergot, blocks a1 and a2 adrenoceptors. Has dofaminergichesky, serotonergic effect, reduces aggregation of thrombocytes and erythrocytes, reduces permeability of a vascular wall, increases quantity of the functioning capillaries, improves blood circulation and processes of metabolism in a brain, increases resistance of tissues of brain to a hypoxia.

Caffeine possesses psychogogic and analeptical action, strengthens processes of excitement in a cerebral cortex increases intellectual and physical effeciency, reduces fatigue and drowsiness, increases reflex irritability of a spinal cord, excites the respiratory and vasomotor centers, has diuretic effect.

Pharmacokinetics. At пероралыюм reception, absorption of a digidroergokriptin accelerates in the presence of caffeine (time of achievement of the maximum concentration 0,5 hours).

The maximum concentration after intake of 8 mg of a-digidroergokriptina makes 227 pg/ml, and semi-removal time — less than 2 hours.

Indications to use:

• the decrease in intellectual activity, disturbance of attention and memory, disturbance of orientation in space caused by age changes;
• cerebrovascular insufficiency (including owing to cerebral atherosclerosis);
• effects of disturbance of cerebral circulation;
• prevention of migraine;
• vestibular and labyrinth disturbances (dizziness, sonitus, gipoakuziya) of ischemic genesis;
• Menyer's disease;
• retinopathy (diabetic and hypertensive);
• disturbances of peripheric arterial circulation (syndrome and Raynaud's disease);
• venous insufficiency.

Route of administration and doses:

Inside (during food, with a small amount of liquid) on 12-1 tablet 2 times a day. Duration of a course of treatment 2-3 months, if necessary it is possible to treat 1-2 times a year.

Features of use:

Vazobral has vasodilating effect, without influencing system arterial pressure. Vazobral's appointment the patient with arterial hypertension does not exclude need use of anti-hypertensive means. The caffeine which is contained in drug can cause a sleep disorder, tachycardia.

Side effects:

From digestive tract: nausea, a gastralgia, dyspepsia, at these manifestations drug withdrawal is not required. Seldom (no more than 1% of cases) - dizziness, excitement, a headache. Very seldom (no more than 0,1% of cases) allergic reactions, tachycardia, hypotension are possible.

Interaction with other medicines:

At co-administration of Vazobral and hypotensive drugs development of arterial hypotonia is possible. Caffeine weakens action of hypnagogues.

Contraindications:

The increased individual sensitivity to drug components.

Pregnancy and period of a lactation,
There are no clinical data about Vazobral's uses during pregnancy and feeding by a breast. Use of drug during breastfeeding can lead to reduction of a lactation.

Overdose:

Symptoms - strengthening of expressiveness of side effects.
Symptomatic treatment.

Storage conditions:

List B. At a temperature of 15 - 25 °C, in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

On 10 tablets in a blister strip packaging. On 1 or 3 packagings in a cardboard box together with the application instruction.